^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ROR1 inhibitor

    Related drugs:
    21d
    A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies. (PubMed, Front Immunol)
    Our findings demonstrate that 22.0405.aF exhibits far superior ADCC activity compared to anti-ROR1 antibodies, e.g. zilovertamab and R12, tested in clinical trials thus far. 22.0405.aF displayed potent tumor cell killing, both in vitro and in vivo, and induced more potent killing of patient-derived malignant B-cells ex vivo compared to rituximab, without affecting healthy B-cells...These results underscore the therapeutic potential of 22.0405.aF as a promising immunotherapy for treatment of ROR1-positive B-cell malignancies. Notably, 22.0405.aF has recently completed Phase 0 clinical trials in patients with head and neck carcinomas and soft tissue sarcomas, paving the way for further clinical development.
    Journal • IO biomarker
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    Rituxan (rituximab) • zilovertamab (UC-961)
    4ms
    A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    nebratamig (GNC-035)
    4ms
    GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    nebratamig (GNC-035)
    4ms
    A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=3, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=40 --> 3
    Enrollment closed • Enrollment change
    |
    nebratamig (GNC-035)
    4ms
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=58 --> 33
    Enrollment closed • Enrollment change
    |
    nebratamig (GNC-035)
    4ms
    GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=29, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    nebratamig (GNC-035)
    4ms
    A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    nebratamig (GNC-035)
    4ms
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=58, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    nebratamig (GNC-035)
    5ms
    PBL-0405-01: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=8, Completed, Pure Biologics S.A. | Recruiting --> Completed
    Trial completion
    7ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Terminated, Numab Therapeutics AG | N=180 --> 11 | Trial completion date: Dec 2027 --> Apr 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Apr 2025; Business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    8ms
    Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity. (PubMed, J Med Chem)
    This effort produced a series of 1-methyl-3-(pyridin-3-yl)-1H-indole derivatives, culminating in the discovery of compound 24d. This lead candidate demonstrates exceptional ROR1 inhibitory potency, high selectivity, robust antitumor activity in vitro and in vivo, and an optimized PK profile, marking a substantive advance toward selective ROR1 inhibitors.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    8ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Active, not recruiting, Numab Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed